Peptieds

AOD9604 VIAL

Peptid AOD 9604

Name: AOD9604 /Peptide AOD 9604

Form:  Sterile Filtered White lyophilized (freeze-dried) powder.

Dosage: 2mg/vial

Top color: Usually Black / blue / green / golden. 

Inventory: 10000 vials for sell.

MOQ: 100 vials

Package:  10vials/kit. 10kits/bag/carton 

Pack material: Shockproof film, shockproof envelope, and Cartons.  

Logo:  with or without both ok. 

OEM: Offer OEM service. Customed dosage & brand & LOGO & package & top color. OEM MOQ 100kits (=1000vials)

Shipment: By express to buyers’ door. 100% make sure delivery. 

Payment: TT/ Western Union/BTC/ETV/VISA and so on, please contact by email. 

Shipment time: Within three working days after payment. Usually need ten days to arrive buyers’ address. Resend if lost.


1.2.jpg


DESCRIPTION

Background: The human growth hormone (hGH) has properties making it a potential candidate to treat obesity, however safety issues limit its long-term use. AOD9604 is a peptide fragment of the C-terminus of hGH (Tyr-hGH177-191), which harbors the fat reducing activity of hGH, without its negative effects. In this paper the safety data of AOD9604 obtained in clinical trials are summarized.

Methods: Six randomized, double-blind, placebo-controlled trials were performed with AOD9604. Special focus was given to undesired effects associated with hGH treatment: increases in IGF-1 levels, insulin resistance, and impaired glucose tolerance. Blood samples were analyzed for presence of anti-AOD9604 antibodies to exclude immunogenicity.

Results: AOD9604 had no effect on serum IGF-1 levels, which confirms the hypothesis that AOD9604 does not act via IGF-1. Results of oral glucose tolerance test demonstrated that, in contrast with hGH, AOD9604 has no negative effect on carbohydrate metabolism. There were no anti-AOD9604 antibodies detected in any of the patients selected for antibody assay. In none of the studies did a withdrawal or serious adverse event occur related to intake of AOD9604.

Conclusion: AOD9604 displayed a very good safety and tolerability profile indistinguishable from placebo. AOD9604 did not result in any of the adverse effects associated with full-length hGH treatment.

Keywords: AOD9604; Peptide fragment; C-terminus of Human growth hormone; Clinical trial


The human growth hormone (hGH) is a 191-amino acid long, single-chain polypeptide secreted by the pituitary gland under the regulation of the hypothalamus. It regulates a variety of biological processes in various tissues. When binding to the hGH-receptor it activates one of various signaling cascades, depending on the tissue. In the liver hGH induces the secretion of Insulin-Like Growth Factor-1 (IGF-1). IGF-1 can stimulate growth in almost every tissue in the body, including skeletal muscle, cartilage, bone, liver, kidney, nerves etc. [1].

The hGH plays different roles over the entire life time of a human being. For example, in children the most obvious function of hGH is promoting growth, but hGH also plays an important role in adults in metabolism [2, 3].

Amongst its metabolic effects, hGH can induce inhibition of lipoprotein lipase activity in adipose tissue, stimulating lipolysis in adipocytes, which results in the reduction of fat cell mass [4-7]. Moreover, a correlation has been found between adiposity and the reduced circulating levels of hGH [8]. When applied systemically, hGH reduces body fat mass and influences fat distribution [9]. Therefore, treatment with hGH should theoretically have a positive impact on obesity. However, long term treatment with hGH is associated with various health risks, including glucose intolerance and insulin resistance, diabetes, acromegaly, cancer, edema, and hypertension [10-13].

In plasma, different isoforms and fragments of hGH were found [10]. Research on specific domains and fractions of the protein revealed that they can be assigned to different actions of the protein: In vitro and in vivo experiments have shown that several fragments of the amino terminal region of hGH, namely 1-15, 1-42, 6-13, and 32-46, exhibit an insulin-potentiating action [14-16]. The region hGH 108-129 was found to evoke high mitogenic responses [17], while the carboxy terminus hGH177-191 seemed to be a lipid mobilizing domain, inhibiting the acetyl-CoA carboxylase activity in adipocytes and hepatocytes [18].

AOD9604 is a peptide fragment of the C-terminus of human growth hormone (Tyr-hGH177-191). It is prepared by solid phase peptide synthesis and contains an additional tyrosine residue at the N-terminal end that stabilizes the peptide. Investigation on the secondary structure of AOD9604 showed similarities to the homologous region in the naturally occurring hGH molecule [19]. Animal experiments confirmed the fat reducing potential of AOD9604, which seems to act directly on fat metabolism without influencing appetite. In genetically obese strains of rats and mice, AOD9604 was shown to affect body weight reduction, stimulation of lipolysis and inhibition of lipogenesis. Adverse effects, as seen in similar studies using intact hGH [18, 20, 21], were not observed with AOD9604 supplementation.

Recently, AOD9604 was determined by an appropriately qualified GRAS panel of experts who are qualified by scientific training and experience to be ‘Generally Recognized As Safe’ (GRAS) under conditions of intended uses of AOD9604 in foods.

In order to demonstrate safety, several human studies were performed with AOD9604 (supplementary data): 1). METAOD001: A Phase I (double-blind, placebo-controlled, dose escalation) safety study with doses (ranging from 25 to 400 µg/kg AOD9604) administered intravenously to 15 healthy adult male volunteers presenting with a BMI between 24 and 30 kg/m2. A single dose of recombinant hGH (0.12 international units/kg) was administered intravenously as positive control. 2). METAOD002: A Phase IIa (double-blind, placebo-controlled 4 × 4 Latin Square design) safety study with single doses (25, 50 and 100 µg/kg AOD9604) administered intravenously to 23 healthy clinically obese males presenting with a BMI ≥ 35 kg/m2. 3). METAOD003: A Phase IIa (double-blind, placebo-controlled 4 × 4 Latin Square design) safety study with single doses (9, 27 and 54 mg AOD9604) administered orally (capsules) to 17 healthy, clinically obese males presenting with a BMI ≥ 35 kg/m2. 4). METAOD004: A Phase IIa (double-blind, placebo-controlled, dose escalation) safety study with multiple daily doses (9, 27 or 54 mg AOD9604) administered orally (capsules) for seven days in 36 healthy clinically obese males presenting with a BMI ≥ 30 kg/m2. 5). METAOD005: A Phase IIb (randomized, double-blind, placebo-controlled) study to assess the efficacy (reduction in body weight), safety and tolerability of 12 weeks treatment with daily doses (1, 5, 10, 20 or 30 mg AOD9604) administered orally (capsules) in 300 healthy, clinically obese males, and females of non-child bearing potential, with a BMI ≥ 35 kg/m2. 6). METAOD006: A Phase IIb, randomized, double-blind, placebo-controlled study to assess the efficacy (reduction in body weight), safety and tolerability of 24 weeks treatment with different doses of AOD9604 tablets (0.25 mg, 0.5 mg, 1 mg, or placebo) in 502 obese adults.

The objective of this paper is to summarize and discuss the safety and tolerability data obtained from these human clinical trials.


The fat-burning truth about AOD 9604

If fighting fat is weighing heavily on your mind, then it’s time to see the light about AOD 9604. Originally created as an anti-obesity remedy, this slimming solution has recently found fame for its natural ability to help you burn fat and increase your weight loss results. Get the skinny on this fat-fighting peptide.


Why lean on AOD 9604

AOD 9604 has become a real heavyweight among people looking to become both leaner and lighter. While many consider it a weight loss wonder, this peptide is actually a fragment of human growth hormone (HGH). It’s natural ability to stimulate the pituitary gland helps to speed up your metabolism, which helps you burn fat and boosts your calorie burn—all without increasing your hunger or blood sugar.


Weigh the many benefits of AOD 9604

Fat doesn’t stand a chance against this naturally powerful peptide, whose impressive fat-fighting abilities can provide the following benefits, such as:

 

How AOD 9604 helps to tip the scales in your favor


If overdose is suspected

If you think there has been an overdose, call your poison control center or get medical care right away. Be ready to tell or show what was taken, how much, and when it happened.


Consumer information use


Warnings

PELIOSIS HEPATIS, A CONDITION IN WHICH LIVER AND SOMETIMES SPLENIC TISSUE IS REPLACED WITH BLOOD-FILLED CYSTS, HAS BEEN REPORTED IN PATIENTS RECEIVING ANDROGENIC ANABOLIC STEROID THERAPY. THESE CYSTS ARE SOMETIMES PRESENT WITH MINIMAL HEPATIC DYSFUNCTION, BUT AT OTHER TIMES THEY HAVE BEEN ASSOCIATED WITH LIVER FAILURE. THEY ARE OFTEN NOT RECOGNIZED UNTIL LIFE-THREATENING LIVER FAILURE OR INTRA-ABDOMINAL HEMORRHAGE DEVELOPS. WITHDRAWAL OF DRUG USUALLY RESULTS IN COMPLETE DISAPPEARANCE OF LESIONS. LIVER CELL TUMORS ARE ALSO REPORTED. MOST OFTEN THESE TUMORS ARE BENIGN AND ANDROGEN-DEPENDENT, BUT FATAL MALIGNANT TUMORS HAVE BEEN REPORTED. WITHDRAWAL OF DRUG OFTEN RESULTS IN REGRESSION OR CESSATION OF PROGRESSION OF THE TUMOR. HOWEVER, HEPATIC TUMORS ASSOCIATED WITH ANDROGENS OR ANABOLIC STEROIDS ARE MUCH MORE VASCULAR THAN OTHER HEPATIC TUMORS AND MAY BE SILENT UNTIL LIFE-THREATENING INTRA-ABDOMINAL HEMORRHAGE DEVELOPS. BLOOD LIPID CHANGES THAT ARE KNOWN TO BE ASSOCIATED WITH INCREASED RISK OF ATHEROSCLEROSIS ARE SEEN IN PATIENTS TREATED WITH ANDROGENS AND ANABOLIC STEROIDS. THESE CHANGES INCLUDE DECREASED HIGH-DENSITY LIPOPROTEIN AND SOMETIMES INCREASED LOW-DENSITY LIPOPROTEIN. THE CHANGES MAY BE VERY MARKED AND COULD HAVE A SERIOUS IMPACT ON THE RISK OF ATHEROSCLEROSIS AND CORONARY ARTERY DISEASE.


How do I store and/or throw out?

If you need to store it at home, talk with your doctor, nurse, or pharmacist about how to store it.

PROTECT FROM LIGHT. Store in carton until contents are used.


ATTENTION: All these products are strictly for LABORATORY AND RESEARCH PURPOSES ONLY. They are not to be used for any human and veterinary purposes.